Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 Jun 26;9(6):e101119.
doi: 10.1371/journal.pone.0101119. eCollection 2014.

Prognostic value of PLR in various cancers: a meta-analysis

Xin Zhou  1 , Yiping Du  1 , Zebo Huang  1 , Jun Xu  1 , Tianzhu Qiu  1 , Jian Wang  1 , Tongshan Wang  1 , Wei Zhu  1 , Ping Liu  1
Affiliations
Meta-Analysis

Prognostic value of PLR in various cancers: a meta-analysis

Xin Zhou et al. PLoS One. .

Abstract

Background: Recently, more and more studies investigated the association of inflammation parameters such as the Platelet Lymphocyte Ratio (PLR) and the prognosis of various cancers. However, the prognostic role of PLR in cancer remains controversial.

Methods: We conducted a meta-analysis of published studies to evaluate the prognostic value of PLR in various cancers. In order to investigate the association between PLR and overall survival (OS), the hazard ratio (HR) and its 95% confidence interval (CI) were calculated.

Results: A total of 13,964 patients from 26 studies were included in the analysis. The summary results showed that elevated PLR was a negative predictor for OS with HR of 1.60 (95%CI: 1.35-1.90; Pheterogeneity <0.001). Subgroup analysis revealed that increased PLR was a negative prognostic marker in patients with gastric cancer (HR = 1.35, 95%CI: 0.80-2.25, Pheterogeneity = 0.011), colorectal cancer (HR = 1.65, 95%CI: 1.33-2.05, Pheterogeneity = 0.995), hepatocellular carcinoma (HR = 3.07, 95% CI: 2.04-4.62, Pheterogeneity = 0.133), ovarian cancer (HR = 1.57, 95%CI: 1.07-2.31, Pheterogeneity = 0.641) and non-small cell lung cancer (NSCLC) (HR = 1.85, 95% CI: 1.42-2.41, Pheterogeneity = 0.451) except for pancreatic cancer (HR = 1.00, 95%CI: 0.92-1.09, Pheterogeneity = 0.388).

Conclusion: The meta-analysis demonstrated that PLR could act as a significant biomarker in the prognosis of various cancers.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Methodological flow diagram of the meta-analysis.
Figure 2
Figure 2. Forrest plots of studies evaluating hazard ratios (HRs) of PLR for overall survival.
Figure 3
Figure 3. Effect of individual studies on the pooled HR for PLR and OS of patients.
Figure 4
Figure 4. Funnel plots of studies included in the meta-analysis.
See this image and copyright information in PMC

References

    1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11–30. - PubMed
    1. Paul D, Kumar A, Gajbhiye A, Santra MK, Srikanth R (2013) Mass spectrometry-based proteomics in molecular diagnostics: discovery of cancer biomarkers using tissue culture. Biomed Res Int 2013: 783131. - PMC - PubMed
    1. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454: 436–444. - PubMed
    1. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357: 539–545. - PubMed
    1. Mantovani A, Romero P, Palucka AK, Marincola FM (2008) Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 371: 771–783. - PubMed

Publication types

LinkOut - more resources